Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(186)
•••
Comment by robertshawon Jul 02, 2019 9:01pm
115 Views
Post# 29881662

RE:RE:RE:Excellent Washington Post article on BCG shortage

RE:RE:RE:Excellent Washington Post article on BCG shortage
Claridge wrote: Laserstock29 ... "In due time" because so far, we have not treated one Ph. 2b patient.  And it will take more than just one also.  And more than just 3-month data from 5 Ph. 2b patients.

The article clearly states why Sanofi stopped manufacturing BCG.  I'll let you read the whle article.


Hi, Ben, phase 2 human trial supposed to start at early Q2, right? But we're now in early Q3 and still didn't get any news regarding the treatment plan, did all of the participate human trial hospitals like PMH just enroll patients as a hobby of collecting old stamps for fun or what, why not even just get 1 patient treated first? With this uncertainty, blowjobjoe's fu?king boss is now manipulating the share price down every day at its best, and screwed all the long suffered shareholders...
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities